Evidence map›Paper›PMID 33787657›Full record

ArticleClinics (Sao Paulo, Brazil)

Modelling the impact of contact tracing of symptomatic individuals on the COVID-19 epidemic.

Marcos Amaku, Dimas Tadeu Covas, Francisco Antonio Bezerra Coutinho, Raymundo Soares Azevedo, Eduardo Massad

Abstract read
In one paragraph

Article in Clinics (Sao Paulo, Brazil). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Observational
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Marcos AmakuLaboratorio de Investigacao Medica (LIM01), Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, BR.ORCID http://orcid.org/0000-0003-4752-6774
Dimas Tadeu CovasInstituto Butantan, Sao Paulo, SP, BR.ORCID http://orcid.org/0000-0002-7364-2595
Francisco Antonio Bezerra CoutinhoLaboratorio de Investigacao Medica (LIM01), Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, BR.ORCID http://orcid.org/0000-0003-3127-3071
Raymundo Soares AzevedoLaboratorio de Investigacao Medica (LIM01), Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, BR.ORCID http://orcid.org/0000-0003-0660-2371
Eduardo MassadLaboratorio de Investigacao Medica (LIM01), Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, BR.ORCID http://orcid.org/0000-0002-7200-2916

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesWith the declining numbers of coronavirus disease 2019 (COVID-19) cases in the state of São Paulo, Brazil, social distancing measures have gradually been lifted. However, the risk of a surge in the number of cases cannot be overlooked. Even with the adoption of nonpharmaceutical interventions, such as restrictions on mass gatherings, wearing of masks, and complete or partial closure of schools, other public health measures may help control the epidemic. We aimed to evaluate the impact of the contact tracing of symptomatic individuals on the COVID-19 epidemic regardless of the use of diagnostic testing.

methodsWe developed a mathematical model that includes isolation of symptomatic individuals and tracing of contacts to assess the effects of the contact tracing of symptomatic individuals on the COVID-19 epidemic in the state of São Paulo.

resultsFor a selection efficacy (proportion of isolated contacts who are infected) of 80%, cases and deaths may be reduced by 80% after 60 days when 5000 symptomatic individuals are isolated per day, each of them together with 10 contacts. On the other hand, for a selection efficacy of 20%, the number of cases and deaths may be reduced by approximately 40% and 50%, respectively, compared with the scenario in which no contact-tracing strategy is implemented.

conclusionContact tracing of symptomatic individuals may potentially be an alternative strategy when the number of diagnostic tests available is not sufficient for massive testing.

Indexed as

COVID-19EpidemicsBrazilContact TracingHumansSARS-CoV-2

Identifiers

PMID33787657
PMCPMC7978843

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.